Log in

RegulatoryEconomic Times

NATCO Pharma receives FDA Establishment Inspection Reprot for Vishakhapatnam plant

Negative-335 sources

GreyOak summary

NATCO Pharma announced it received an Establishment Inspection Report (EIR) from the US FDA regarding its Vishakhapatnam plant. The inspection, conducted between August 17 and 21, resulted in four observations listed on Form-483. The FDA classified the inspection as Voluntary Action Indicated (VAI).

What it affects

Source

Reported by Economic Times

  • Business Today
  • BusinessLine
  • Economic Times
  • Economic Times
  • Economic Times

More Natco Pharma news

All Natco Pharma news →

The company today

Price, day change, sector and market cap of the companies this story names
CompanyPriceDay changeSectorMarket cap
Natco PharmaNATCOPHARM · NSE₹813.40−1.04%Healthcare₹15,956 crore

Prices as of ; the last session's close when the market is shut. Research, not investment advice.

Latest market news

News Intelligence →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy